<p>Apogee Therapeutics, Inc.（納斯達克股票代碼：APGE - 獲取免費報告）股票週三在盤中交易中下跌了 2.7%。該股票的最低交易價為 36.88 美元，最後交易價為 37.16 美元。在盤中交易期間，共有 85,240 股股票交易，較平均交易量 55,863 股下降了 85%。該股票此前收盤價為 38.21 美元。</p>
<p>獲取 <strong>Apogee Therapeutics</strong> 警報：</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>IPO 觀察 2024：哪些新股將上市？</li>
</ul>
<p>一些股票分析師已經就該公司發佈了報告。Stifel Nicolaus 將 Apogee Therapeutics 的目標股價從 46.00 美元上調至 95.00 美元，並在 3 月 5 日星期二的研究報告中給予該公司 “買入” 評級。美國銀行在 5 月 10 日星期五的研究報告中開始對 Apogee Therapeutics 進行覆蓋。他們對該股票發行了 “買入” 評級，並設定了 80.00 美元的目標股價。Guggenheim 將 Apogee Therapeutics 的價格目標從 44.00 美元上調至 91.00 美元，並在 3 月 5 日星期二的研究報告中給予該股票 “買入” 評級。Wedbush 在 5 月 13 日星期一的研究報告中重申了 “表現優異” 評級，並設定了 87.00 美元的價格目標。最後，Jefferies 金融集團將 Apogee Therapeutics 的價格目標從 37.00 美元上調至 75.00 美元，並在 3 月 6 日星期三的研究報告中給予該股票 “買入” 評級。根據 MarketBeat.com，共有八位投資分析師對該股票進行了買入評級，目前該公司的平均評級為 “買入”，平均目標股價為 73.00 美元。</p>
<p><strong>查看我們關於 APGE 的最新報告</strong></p>
<h2>Apogee Therapeutics 股票下跌 1.9%</h2>
<p>該股票的五十日移動平均價為 45.85 美元，兩百日移動平均價為 44.48 美元。</p>
<p>Apogee Therapeutics（納斯達克股票代碼：APGE - 獲取免費報告）最近發佈了其截至 5 月 13 日星期一的財報。公司報告季度每股收益為（0.64）美元，低於分析師對（0.60）美元的共識預期。分析師預計，Apogee Therapeutics, Inc.本財年將發佈-2.64 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>一些大型投資者最近買入和賣出了 Apogee Therapeutics 的股票。EntryPoint Capital LLC 在第一季度將其在 Apogee Therapeutics 的持倉增加了 44.7%。EntryPoint Capital LLC 現在擁有該公司股票 1,997 股，價值 133,000 美元，較上一季度增加了 617 股。Kennedy Capital Management LLC 在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 212,000 美元。Ameritas Investment Partners Inc.在第一季度將其在 Apogee Therapeutics 的持股增加了 111.2%。Ameritas Investment Partners Inc.現在擁有該公司股票 4,126 股，價值 274,000 美元，較上一季度增加了 2,172 股。Principal Financial Group Inc.在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 339,000 美元。最後，Virtu Financial LLC 在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 362,000 美元。該股票的 79.04% 由機構投資者和對沖基金持有。</p>
<h2>關於 Apogee Therapeutics（獲取免費報告）</h2>
<p>Apogee Therapeutics, Inc.及其子公司經營一家生物技術公司，開發用於治療特應性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相關炎症和免疫疾病指標的生物製劑。該公司主要開發 APG777，用於 AD 的皮下（SQ）延長半衰期單克隆抗體（mAb）；以及 APG808，用於 COPD 的 SQ 延長半衰期 mAb。</p>
<h2>精選故事</h2>
<ul>
<li>我們比 Apogee Therapeutics 更喜歡的五隻股票</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>AbbVie 股票：投資者購買的完美機會</li>
<li>低 PE 增長股：開啓投資機會</li>
<li>忘記 NVIDIA：超微計算機股領先於動量</li>
<li>什麼是 WallStreetBets 以及他們瞄準哪些股票？</li>
<li>GitLab 股票反彈：其復甦內幕故事</li>
</ul>
<p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ [突破] “販毒者” 治癒腦疾？（來自市場背後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Apogee Therapeutics 股票？</h2>
<p>在考慮購買 Apogee Therapeutics 股票之前，您可能希望聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票... Apogee Therapeutics 不在名單上。</p>
<p>儘管 Apogee Therapeutics 目前在分析師中具有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

APGE

<p>Apogee Therapeutics（納斯達克股票代碼：APGE）股價在午間交易中下跌了 2.7%。該股票最低交易價為$36.88，最後交易價為$37.16。平均交易量下降了 85%，成交量為 85,240 股。該股票的 50 天移動平均價為$45.85，200 天移動平均價為$44.48。該公司報告了低於預期的季度盈利結果。多位分析師將該股票評為 “買入”，平均目標價為$73.00</p>

<p>Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) shares traded down 2.7% during mid-day trading on Wednesday . The stock traded as low as $36.88 and last traded at $37.16. 85,240 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 558,863 shares. The stock had previously closed at $38.21.</p>
<div class="lb-trans"><p>Apogee Therapeutics, Inc.（納斯達克股票代碼：APGE - 獲取免費報告）股票週三在盤中交易中下跌了 2.7%。該股票的最低交易價為 36.88 美元，最後交易價為 37.16 美元。在盤中交易期間，共有 85,240 股股票交易，較平均交易量 55,863 股下降了 85%。該股票此前收盤價為 38.21 美元。</p>
</div><p>Get <strong>Apogee Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Apogee Therapeutics</strong> 警報：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>IPO watch 2024: Which new stocks will hit the market?</li>
</ul>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
<ul>
<li>IPO 觀察 2024：哪些新股將上市？</li>
</ul>
</div><p>Several equities analysts have issued reports on the company. Stifel Nicolaus lifted their target price on Apogee Therapeutics from $46.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Bank of America initiated coverage on Apogee Therapeutics in a research note on Friday, May 10th. They issued a &#34;buy&#34; rating and a $80.00 target price on the stock. Guggenheim boosted their price target on Apogee Therapeutics from $44.00 to $91.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Wedbush restated an &#34;outperform&#34; rating and set a $87.00 price target on shares of Apogee Therapeutics in a research note on Monday, May 13th. Finally, Jefferies Financial Group boosted their price target on Apogee Therapeutics from $37.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and an average target price of $73.00.</p>
<div class="lb-trans"><p>一些股票分析師已經就該公司發佈了報告。Stifel Nicolaus 將 Apogee Therapeutics 的目標股價從 46.00 美元上調至 95.00 美元，並在 3 月 5 日星期二的研究報告中給予該公司 “買入” 評級。美國銀行在 5 月 10 日星期五的研究報告中開始對 Apogee Therapeutics 進行覆蓋。他們對該股票發行了 “買入” 評級，並設定了 80.00 美元的目標股價。Guggenheim 將 Apogee Therapeutics 的價格目標從 44.00 美元上調至 91.00 美元，並在 3 月 5 日星期二的研究報告中給予該股票 “買入” 評級。Wedbush 在 5 月 13 日星期一的研究報告中重申了 “表現優異” 評級，並設定了 87.00 美元的價格目標。最後，Jefferies 金融集團將 Apogee Therapeutics 的價格目標從 37.00 美元上調至 75.00 美元，並在 3 月 6 日星期三的研究報告中給予該股票 “買入” 評級。根據 MarketBeat.com，共有八位投資分析師對該股票進行了買入評級，目前該公司的平均評級為 “買入”，平均目標股價為 73.00 美元。</p>
</div><p><strong>View Our Latest Report on APGE</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 APGE 的最新報告</strong></p>
</div><h2>Apogee Therapeutics Trading Down 1.9 %</h2>
<div class="lb-trans"><h2>Apogee Therapeutics 股票下跌 1.9%</h2>
</div><p>The stock has a fifty day moving average of $45.85 and a 200 day moving average of $44.48.</p>
<div class="lb-trans"><p>該股票的五十日移動平均價為 45.85 美元，兩百日移動平均價為 44.48 美元。</p>
</div><p>Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.04). Analysts expect that Apogee Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apogee Therapeutics（納斯達克股票代碼：APGE - 獲取免費報告）最近發佈了其截至 5 月 13 日星期一的財報。公司報告季度每股收益為（0.64）美元，低於分析師對（0.60）美元的共識預期。分析師預計，Apogee Therapeutics, Inc.本財年將發佈-2.64 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently bought and sold shares of APGE. EntryPoint Capital LLC increased its position in shares of Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $212,000. Ameritas Investment Partners Inc. lifted its stake in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock valued at $274,000 after purchasing an additional 2,172 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $339,000. Finally, Virtu Financial LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $362,000. 79.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近買入和賣出了 Apogee Therapeutics 的股票。EntryPoint Capital LLC 在第一季度將其在 Apogee Therapeutics 的持倉增加了 44.7%。EntryPoint Capital LLC 現在擁有該公司股票 1,997 股，價值 133,000 美元，較上一季度增加了 617 股。Kennedy Capital Management LLC 在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 212,000 美元。Ameritas Investment Partners Inc.在第一季度將其在 Apogee Therapeutics 的持股增加了 111.2%。Ameritas Investment Partners Inc.現在擁有該公司股票 4,126 股，價值 274,000 美元，較上一季度增加了 2,172 股。Principal Financial Group Inc.在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 339,000 美元。最後，Virtu Financial LLC 在第一季度收購了 Apogee Therapeutics 的新頭寸，價值 362,000 美元。該股票的 79.04% 由機構投資者和對沖基金持有。</p>
</div><h2>About Apogee Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Apogee Therapeutics（獲取免費報告）</h2>
</div><p>Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.</p>
<div class="lb-trans"><p>Apogee Therapeutics, Inc.及其子公司經營一家生物技術公司，開發用於治療特應性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相關炎症和免疫疾病指標的生物製劑。該公司主要開發 APG777，用於 AD 的皮下（SQ）延長半衰期單克隆抗體（mAb）；以及 APG808，用於 COPD 的 SQ 延長半衰期 mAb。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Apogee Therapeutics</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Forget NVIDIA: Super Micro Computer Stock Leads in Momentum</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>GitLab Stock Rebounds: The Inside Story of Its Comeback</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們比 Apogee Therapeutics 更喜歡的五隻股票</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>AbbVie 股票：投資者購買的完美機會</li>
<li>低 PE 增長股：開啓投資機會</li>
<li>忘記 NVIDIA：超微計算機股領先於動量</li>
<li>什麼是 WallStreetBets 以及他們瞄準哪些股票？</li>
<li>GitLab 股票反彈：其復甦內幕故事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ [Breakthrough] The &#34;Drug Smuggler&#34; Curing Brain Disease? (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ [突破] “販毒者” 治癒腦疾？（來自市場背後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8641&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apogee Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Apogee Therapeutics 股票？</h2>
</div><p>Before you consider Apogee Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Apogee Therapeutics 股票之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票... Apogee Therapeutics 不在名單上。</p>
</div><p>While Apogee Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Apogee Therapeutics 目前在分析師中具有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Apogee Therapeutics（納斯達克代碼：APGE）股價下跌 2.7%